The document discusses the rapid advancements in biotechnology, particularly in CRISPR therapies, which now exceed 60 clinical trials targeting various diseases. It highlights innovations such as base editing and prime editing that enhance precision in gene therapy. Additionally, it covers the rise of longevity science and brain-computer interfaces, showcasing significant breakthroughs in treating age-related conditions and improving communication for paralyzed patients.
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF or read online on Scribd
0 ratings0% found this document useful (0 votes)
4 views4 pages
5 Tech
The document discusses the rapid advancements in biotechnology, particularly in CRISPR therapies, which now exceed 60 clinical trials targeting various diseases. It highlights innovations such as base editing and prime editing that enhance precision in gene therapy. Additionally, it covers the rise of longevity science and brain-computer interfaces, showcasing significant breakthroughs in treating age-related conditions and improving communication for paralyzed patients.
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF or read online on Scribd
— B10TECHNOLOGY & HEALTH
Rewriting Life's Code: The Biotech
Revolution Accelerates
By [Link] —Februsry 16 1610212026, 15:43 TECHNOVA— Technology & Innovation Magazine
Since then, the pipeline has exploded: over 60 CRISPR therapies are now
in clinical trials targeting cancers, inherited blindness, cardiovascular
disease, and HIV.
The technical advances that have made this possible extend far beyond the original Cas9
scissor mechanism. Base editing allows precise single-letter changes to the genetic code
without cutting the double helix — reducing off-target effects dramatically. Prime editing,
sometimes called a "genomic word processor,” can insert, delete, or rewrite any DNA
sequence at any location with unprecedented precision. The tools available to gene
therapists in 2026 are qualitatively different from those of even three years ago.
60+ 15 $890B 120+
CRISPR FDA-APPROVED GLOBAL BIOTECH LONGEVITY
THERAPIES IN GENE THERAPIES MARKET ‘STARTUPS
TRIALS FUNDED
Longevity science has emerged from the
fringes to become a mainstream biotech
category. Geroscience — the study of
aging's biological mechanisms — has
identified multiple "hallmarks of aging” that
can be targeted pharmacologically.
Senolytics, compounds that clear aged
"zombie’ cells from the body, are in Phase Il
trials for multiple age-related conditions.
GLP-1 receptor agonists, originally
developed for diabetes, are demonstrating
{iei/7C:/Usere/DeliDownloadsiTechNova, [Link]!
24 6102/2026, 16:42 TECHNOVA— Technology & Innovation Magazine
NE : =
Brain-computer interfaces have taken their
most significant leap forward since
theoretical conception. Neuralink's
second-generation implant demonstrated
bidirectional communication at 10,000
channels — enabling a paralyzed patient to
control a computer interface, a robotic
arm, and communicate in real-time with
less than 50ms latency. Non-invasive BCs
using advanced neural signal decoding
algorithms are beginning to close the
performance gap with implanted systems.
We are not treating disease anymore. We are beginning
MCRL RY | ee MELE ORO ELL
Mae ROL MOA
ia
— DR. AUBREY DE GREY, LONGEVITY RESEARCH INSTITUTE
TS Ce edo)
{ie:HHC:/Users/DelyDownloads/TechNova_Magazine.htm! ia HNOVA — Technology & Innovation Magazine
intervention
eliDownloads/TectNova_ [Link]